Collegium Pharmaceutical (COLL)
(Delayed Data from NSDQ)
$38.93 USD
-0.41 (-1.04%)
Updated Oct 17, 2024 04:00 PM ET
After-Market: $38.90 -0.03 (-0.08%) 6:40 PM ET
2-Buy of 5 2
A Value A Growth F Momentum A VGM
Income Statements
Fiscal Year end for Collegium Pharmaceutical, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 567 | 464 | 277 | 310 | 297 |
Cost Of Goods | 241 | 254 | 126 | 130 | 194 |
Gross Profit | 326 | 209 | 151 | 180 | 103 |
Selling & Adminstrative & Depr. & Amort Expenses | 159 | 176 | 133 | 124 | 127 |
Income After Depreciation & Amortization | 167 | 33 | 18 | 56 | -24 |
Non-Operating Income | -8 | 1 | 0 | 0 | 2 |
Interest Expense | 83 | 63 | 21 | 29 | 1 |
Pretax Income | 76 | -29 | -3 | 28 | -23 |
Income Taxes | 28 | -4 | -75 | 1 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | 48 | -25 | 72 | 27 | -23 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | 48 | -25 | 72 | 27 | -23 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 315 | 172 | 87 | 118 | -8 |
Depreciation & Amortization (Cash Flow) | 148 | 139 | 69 | 62 | 15 |
Income After Depreciation & Amortization | 167 | 33 | 18 | 56 | -24 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 41.79 | 33.83 | 41.05 | 35.15 | 33.45 |
Diluted EPS Before Non-Recurring Items | 4.99 | 3.53 | 0.34 | 0.76 | -0.68 |
Diluted Net EPS (GAAP) | 1.29 | -0.74 | 1.86 | 0.76 | -0.68 |
Fiscal Year end for Collegium Pharmaceutical, Inc falls in the month of December .
All items in Millions except EPS data.
9/30/24 | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | |
---|---|---|---|---|---|
Sales | NA | 145.28 | 144.92 | 149.75 | 136.71 |
Cost Of Goods | NA | 54.47 | 53.47 | 55.12 | 56.40 |
Gross Profit | NA | 90.81 | 91.46 | 94.63 | 80.31 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 43.34 | 41.98 | 32.94 | 35.30 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | 47.47 | 49.48 | 61.69 | 45.01 |
Non-Operating Income | NA | -2.79 | 4.49 | 4.30 | 4.54 |
Interest Expense | NA | 15.59 | 17.34 | 19.28 | 20.77 |
Pretax Income | NA | 29.10 | 36.62 | 46.71 | 28.78 |
Income Taxes | NA | 9.49 | 8.91 | 14.77 | 8.15 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | 19.61 | 27.71 | 31.94 | 20.63 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | 19.61 | 27.71 | 31.94 | 20.63 |
Earnings Per Share Data | 9/30/24 | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 |
---|---|---|---|---|---|
Average Shares | NA | 40.38 | 41.44 | 41.28 | 42.06 |
Diluted EPS Before Non-Recurring Items | NA | 1.43 | 1.32 | 1.45 | 1.21 |
Diluted Net EPS (GAAP) | NA | 0.52 | 0.71 | 0.93 | 0.53 |